Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Found 432 record(s)

Req # A-2020-00004

List of mandatory or voluntary training, info sessions, awareness sessions, and sensitivity training from January 1, 2020 to September 2020.

Organization: Patented Medicine Prices Review Board Canada

4 page(s)
September 2020

Req # A-2020-04135

Copies of the Human Drug Advisory (HDAP) report for erenumab (Aimovig) from January 2018 to February 2020.

Organization: Patented Medicine Prices Review Board Canada

79 page(s)
September 2020

Req # A-2020-09098

Copies of all records discussing the impacts of the regulatory changes to the PMPRB from August 2019 until August 2020. Copies of all correspondence from all pharmaceutical companies expressing their concerns with the changes and any responses back to these companies. Copies of all correspondence from all advocating groups expressing concerns with the changes and any responses back to these groups. Copies of all correspondence between departmental staff discussing the impacts of the regulatory changes to the PMPRB. Copies of all records discussing the impacts of the PMPRB changes on individuals living with rare diseases. Copies of all correspondence from Vertex Pharmaceuticals relating to Kalydeco, Orkambi, Symdeko, and Trikafta. Copies of all correspondence between government officials (Prime Minister, Ministers, all members of parliament, constituency staff, deputies, assistant deputies, directors, managers, supervisors, staff, and any other employee of the Government of Canada relating to the PMPRB regulatory changes. Copies of all presentations relating to the PMPRB regulatory changes.

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
September 2020

Nothing to report this month

Organization: Northern Pipeline Agency Canada

September 2020